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Background: The use of adenoviral vector for gene therapy is still an important strategy for advanced cancers,
however, the lack of the requisite coxsackie-adenovirus receptor in cancer cells and host immune response to
adenovirus limit the application of adenoviral vector in vivo.
Method: We designed the antiangiogenic gene therapy with recombinant PEDF adenovirus (Ad-PEDF) encapsulated
in cationic liposome (Ad-PEDF/Liposome), and investigated the anti-tumor efficacy of Ad-PEDF/Liposome complex on
inhibition of tumor metastasis.
Results: We found that systemic administration of Ad-PEDF/liposome was well tolerated and resulted in marked
suppression of tumor growth, and was more potent than uncoated Ad-PEDF to induce apoptosis in B16-F10
melanoma cells and inhibit murine pulmonary metastases in vivo. After Ad-luciferase was encapsulated with liposome,
its distribution decreased in liver and increased in lung. The anti-Ad IgG level of Ad-PEDF/Liposome was significantly
lower than Ad-PEDF used alone.
Conclusion: The present findings provide evidences of systematic administration of cationic liposome-encapsulated
Ad-PEDF in pulmonary metastatic melanoma mice model, and show an encouraging therapeutic effect for further
exploration and application of more complexes based on liposome-encapsulated adenovirus for more cancers.
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Melanoma is a tumor of transformed melanocytes; and
it is a potentially serious type of skin cancer [1], which is
one of the most highly invasive and metastatic tumors.
Malignant melanoma is an increasingly common malig-
nancy, and its mortality rates have been rapidly increas-
ing above those of any other cancer in recent years [2,3].
Melanoma can spread "silently" at an early stage without
any symptoms of metastasis, and owing to the incidence
of melanoma is increasing in last decades, the mortality rate
of melanoma is still increasing [3]. Thus, it is imminent to* Correspondence: lixiaopeng7206@163.com; yl.tracy73@gmail.com
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reproduction in any medium, provided the orseek new strategies for treating patients with melanoma
who are at high risk of metastasis.
Angiogenesis plays a critical role in the process of
growth and metastasis of primary solid tumors [4,5].
The endothelial cells are genetically stable and have no
resistance via repeated administration [6-8]; so anti-
tumor therapy is aimed at endothelial cells by inhibiting
neovascularization and interrupting blood supplication
for tumor, which could slow down the tumor growth
[9,10]. The current review summarizes existing know-
ledge of the mechanisms of angiogenesis in melanoma
[11], and current anti-angiogenic therapeutic strategies
and their targets confirmed the effect of anti-angiogenic
therapy on melanoma [12-15].
Pigment epithelium-derived factor (PEDF) is a 50-kDa
protein isolated from conditioned media of the retinal
pigment epithelial cells as a potent endogenous inhibitor. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and migration of endothelial cells toward many angio-
genic inducer, including platelet-derived growth factor,
vascular endothelial growth factor (VEGF), interleukin-8,
acidic fibroblast growth factor, and lysophosphatidic acid
[17], and then suppress angiogenesis. PEDF could prevent
melanoma growth via angiogenesis inhibition [2,18]. The
lack of PEDF expression may contribute to the pathogen-
esis of malignant melanoma [19]. Therefore, over expres-
sion of PEDF could inhibit angiogenesis and the growth of
malignant melanoma cells [18]. However, there are some
setbacks in clinical application with PEDF due to difficul-
ties and the high cost of producing large quantities of
biologically active proteins and the short half-life of PEDF
[17]. Gene therapy offers a preferable pathway to solve
these problems.
Adenoviral vector (Ad) is the widely utilized vehicle for
gene transfer in a variety of gene therapies, because they
can transfect many cell types [20-23]. However, due to the
innate immunogenicity of adenovirus and its targeting cel-
lular receptor dependency, such as Coxsackie-adenovirus
receptor (CAR), the therapeutic effect of gene transfer
therapy decreases. In addition, no better effect could been
gained by repeating administration [24,25], as drugs only
accumulate in the liver other than transport to other nor-
mal tissues when intravenous administration of an adeno-
virus vector [26,27]. Fortunately, recent studies suggest
that Ad encapsulated with liposome may be an effective
strategy to escape the neutralization caused by immune
response and enhance gene transfer [28,29]. Given these,
we studied that gene delivery liposome encapsulating
adenovirus-encoding PEDF may be more efficient and
safer treating strategy for improving gene therapy.
In this study, we used anti-angiogenesis with gene
therapy by developing PEDF encoding adenovirus; and
then we used cationic liposome which was composed of
(1, 2-dioleoyloxypropyl)-N, N, N-trimethy-lammonium
chloride DOTAP: chol (cholesterol) to encapsulate the
recombined adenovirus-encoding PEDF. We investigated
the antitumor activities of the intravenous administration
of cationic liposome-encapsulated recombinant PEDF
adenovirus in C57BL/6 mice model that were planted with
B16-F10 melanoma cells. Our study indicates that the
complexes can not only be safe to recipient mice, but also
generate enhanced and lasting antitumor effects in vivo,
and makes for further clinical application.
Methods
Cell lines and animals
B16-F10 cell line and the human embryonic kidney
(HEK293) cell line were obtained from ATCC (American
Type Culture Collection, Manassas, VA), and cultured
in RPMI-1640 or DMEM medium (Gibco/Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovineserum (FBS) plus ampicillin and streptomycin, and incu-
bated in a 5% CO2, 37°C incubator routinely. C57BL/6
mice (6–8 weeks old) were purchased from the Laboratory
Animal Center of Sichuan University. All experiments
were approved by the Institutional Animal Care and
Treatment Committee of Sichuan University (Chengdu,
China).
Recombinant adenoviral vector construction and viral
preparation
A recombined adenovirus carrying PEDF gene (Ad-PEDF)
was prepared as previously described, Ad-luciferase and
Ad-Null was prepared as the construction of Ad-PEDF,
except luciferase gene or no objective gene was inserted
[30]. After Ad-PEDF, Ad-luciferase and Ad-Null was
constructed, the viral particles were amplified in HEK293
cells, which were maintained in DMEM medium with
10% FBS plus ampicillin and streptomycin, and incubated
in a 37°C humidified chamber with 5% CO2 atmosphere.
The harvested viral particles from the cultures were puri-
fied by two-step cesium chloride (CsCl) gradient ultracen-
trifugation and measured by absorption (A260). The virus
titer was quantified using a standard TCID50 assay.
Preparation of cationic liposome
Cationic liposome was prepared as follows. Briefly, choles-
terol and DOTAP (Sigma, USA) were mixed at a molar ra-
tio of 1:1. Then trichloromethane and methanol were
added into the mixture at volume ratio of 3:1. After rotary
evaporation to remove the organic solvents and vacuum
dehydration, the dried lipid film was hydrated with dis-
tilled water. Then the lipid film was ultrasonicated to form
liposome in ice bath and restored in 4°C.
Test of Ad/liposome complexes with transmission
electron microscope (TEM)
The Ad-liposome complexes were visualized under an
electron microscope by using a negative stain. Before TEM
(H7650, Hitachi, Japan) observation, Ad/Liposome com-
plexes were incubated for 30 min at room temperature,
dripped on copper screens covered with nitrocellulose,
followed by phosphotungstic acid for negative staining and
drying in room temperature.
Preparation of adenovirus-liposome complex and
determine the particle size
Fixed amount of adenovirus was added into liposomes,
the suspension was gently mixed and incubated for
30 min at room temperature. The particle diameter was
analyzed using a particle size analyzer (Mastersizer 2000,
USA) after the Ad-liposome complexes were performed.
The resulting Ad-liposome complexes were prepared
fresh at room temperature.
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transfection in B16-F10 melanoma cells by the Ad-GFP/
liposome complexes
B16-F10 melanoma cells were transfected with different
liposome and Ad-GFP ratios. In brief, Cells were seeded
into 6-well plates at a density of 5 × 105 cells per well and
used at 70–80% confluence. Various amounts of liposomes
(2, 5, 10, 15, 20 μg, respectively) were incubated with a
fixed amount of Ad-GFP for 30 min at room temperature,
and then added to B16-F10 melanoma cells. At 72 h
after infection, the percentage of GFP expressing was
determined by Flow Cytometry (FCM) (Epics Elite ESP,
Beckman Coulter, USA).
Effect of neutralizing the antibody in vitro for B16-F10
melanoma cells
Neutralizing antibodies of Ad vector was prepared as
before [31]. After obtained the neutralizing antibodies,
complexes of Ad-GFP and DOTAP and cholesterol cat-
ionic liposomes were used to infect B16-F10 melanoma
cells with or without the serum containing the neutraliz-
ing antibody at 37°C for 4 h. Then, cells were washed with
phosphate-buffered saline to remove the complexes. An-
other 2 ml fresh medium with 10% FBS was added. The
expression of GFP in infected cell samples were visualized
with an Olympus microscope at × 200 magnification after
Cells were incubated for an additional 48 h.
Expression of human PEDF carried by the Ad-PEDF/
liposme complexes in B16-F10 melanoma cells
The procedure was performed as described previously
[30]. Briefly, 5 × 105 B16-F10 melanoma cells were plated
into 6-well plates and used at 70%–80% confluence. Then
the cells were infected with the Ad-PEDF/Liposome
complexes (at a ratio of 5 × 107 i.f.u. Ad-PEDF with
10 μg Liposome), Ad-PEDF or Ad-null. Multiplicity of
infection (MOI) of each groups were 500. After infection
for 72 h, supernatants were collected and stored at −80°C
for western blotting analysis. The proteins of super-
natant were separated by SDS-polyacrylamide gel elec-
trophoresis (PAGE) and electronically transferred onto
a polyvinylidene difluoride membrane (PVDF, Bio-Rad,
Richmond, CA, USA). The blots were probed with a
mouse anti-human PEDF monoclonal antibody (3:1000,
mAb; R&D Systems, Boston, MA, USA) and a peroxidase-
conjugated secondary antibody, goat anti-mouse IgG
(1:10,000, ZSGB-BIO, Beijing, China). The protein bands
were visualized by an enhanced chemiluminescence (ECL)
detection system (Pierce, Rockford, IL, USA).
Detect of apoptosis of B16-F10 melanoma cells in vitro
B16-F10 melanoma cells were plated in 6-well plates with
5 × 105 cells/well and cultured to 70–80% confluence at
37°C in humid air containing 5% CO2. Then, cells wereinfected with Ad-PEDF/Liposome complexes (at a ratio of
5 × 107 IFU. Ad-PEDF with 10 μg Liposome), Ad-PEDF or
Ad-null. Multiplicity of infection (MOI) of each groups
were 500. After infection for 72 h, the efficiency of apop-
tosis for B16-F10 melanoma cells was assayed by Flow
Cytometry.
Luciferase assay for Ad-luc/liposome distribution
The viral distribution was analyzed by using the luciferase
reporting system. In brief, on day 1, all the mice were ran-
domly assigned into 4 groups and each group contained 3
mice. Experimental group received 1 × 108 IFU. Ad-luc
plus 20 μg liposome while the control groups received 1 ×
108 IFU. Ad-Null and 1 × 108 IFU. Ad-luc (Ad-luciferase)
in 0.1 ml normal saline (NS) via i.v. injection, respectively.
Seven days later, the mice were sacrificed. Hearts, livers,
spleens, lungs, and kidneys from each mouse were col-
lected and individually stored in liquid nitrogen. Using a
luciferase assay system kit (Promega, Madison WI, USA),
we analyzed luciferase expression in each type of collected
organs, according to the manufacturer’s instructions.
Briefly, the same organs from the same group were pooled
and ground to a fine powder in a mortar containing liquid
nitrogen. The fine powder was dissolved and further
processed in CCLB solution in the assay kit. The resultant
supernatants were collected and subjected to determin-
ation of relative light units (RLU, synergy 2, Biotek,
Germany), along with a group of standard samples in the
kit. The concentration of luciferase in each sample was
calculated on the basis of the standard curve.
Detection of Ad antibodies concentration in sera
On the other hind, we detected Ad antibodies concentra-
tion in the sera to assess whether encapsulation of lipo-
some can reduce Ad clearance by systemic circulation. In
brief, Ad-Null was diluted to 1 × 109 IFU /ml by 50 mM
carbonate coating buffer (PH9.6). 100 μl diluted Ad-Null
was added to every well of 96-well ELISA plate and the
plate was put at 4°C for overnight. After washing, 150 μl,
1% BSA was added to the plate and blocked at 37°C for 1
hour. Then, after washing, 100 μl different dilution at
multi proportion of sera with positive and negative con-
trols were added and incubated at 37°C for 90 minutes.
After washing, 100 μl goat anti-mouse Ab tagged horse-
radish peroxidase (HRP, 1:5000) was added and incubated
at 37°C for 1 hour. After washing, TMB (3,3´,5,5´
tetramethylbenzidine) as chromogenic agent was added
and incubated for 20 minutes at 37°C, followed by 0.5 M
sulphuric acid as stop solution. The absorbance was read
immediately at 450 nm in a micro-plate reader (3550-UV,
BIO-RAD, USA) and the data was used for statistical
analysis. There were the serum samples mixed form 3
mice in each group, and each sample were applied to 3
replicated wells.
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Six to eight week-old female C57BL/6 mice were permit-
ted one week to acclimate to their environment before
manipulation. B16-F10 melanoma cells 5 × 105 were
injected into C57BL/6 mice by tail vein in 100 μl
phosphate-buffered saline. Five days later, mice were
randomly divided into four groups: (1) Ad-PEDF plus
liposome group (Ad-PEDF/Lipo), i.v. administration of
1 × 108 IFU recombinant adenovirus plus 20 μg lipo-
some; (2) Ad-PEDF group (Ad-PEDF), i.v. administration
of 1 × 108 IFU recombinant adenovirus; (3) Ad-null plus
liposome group (Ad-null/Lipo), i.v. administration of
1 × 108 IFU plus 20 μg liposome; and (4) normal saline
group. To observe therapeutic effects, all of the treat-
ments were performed once. Mice were sacrificed when
become moribund by day 18 in normal saline group and
lungs from sacrificed mice were removed, the weight
and metastasis nodules of lungs were collected; then
lungs were fixed in 4% formaldehyde solution for
immunochemistry staining and histological analysis. To
observe survival time, mice were inoculated in the same
way as above (n = 10 per group) and treated once per
week for 6 weeks; residual mice in all groups were killed
90 days after tumor establishment.
To determine the effect of anti-angiogenesis treatment
of Ad-PEDF/Liposome, frozen tissues were sectioned
(5 mm) and fixed in acetone at 4°C. Sections were
probed with a monoclonal anti-CD31 antibody and a
secondary goat antibody (tetramethylrhodamine isothio-
cyanate TRITC, dilution: 1:200). Then, the sections were
visualized and microvessels were calculated with an
Olympus microscope at × 200 magnification.
Furthermore, the apoptotic cells within the metastatic
site of B16-F10 melanoma tissue were evaluated by a
commercially available TUNEL kit (Promega, Corporation,
Madison, WI, USA), according to the manufacturer’s
protocol.
Statistical analysis
SPSS 13.0 (SPSS Inc., USA) was used for statistical analysis.
ANOVA was used to determine statistical significances in
the comparisons in this study. The difference is considered
as significant if p < 0.05.
Results
Morphological characteristic of Ad-liposome complexes
The complexes of liposome and Ad were verified by a
transmission electron microscope. As the photos of TEM
showed, there was nothing around the naked Ad as con-
trol (Figure 1a), while the adenoviral particles were evenly
encapsulated within the liposome (Figure 1b). The size of
the complexes was between 80–120 nm and the adeno-
viral particles were evenly distributed within the DOTAP
and cholesterol liposome (Figure 1c).Encapsulation of liposome enhances transfection
efficiency of Ad in vitro
The recombined adenovirus-encoding GFP were gener-
ated to detect transfection efficiency for B16-F10 melan-
oma cells. We tried to use fixed amounts of Ad-GFP to
incubate with varying concentrations of liposome and then
infected B16-F10 melanoma cells, deficiency of CAR [32]
(data not shown). We found that Ad-GFP encapsulated
with DOTAP and cholesterol liposome shows increased
transfection ability in B16-F10 melanoma cells. GFP ex-
pression increased and then reached a peak with increas-
ing concentrations of DOTAP and cholesterol liposome
within 10 μg and then Ad-GFP expression was decreased
with increasing concentrations of DOTAP and cholesterol
liposome (Figure 2a). On the basis of these data, we
selected liposome: Ad-GFP ratios of 10 μg: 5 × 107 IFU for
further studies. Then, we detected expression of PEDF in
B16-F10 melanoma cells transfected by the Ad-PEDF/
Liposome complexes for 72 h using western blotting
analysis. As shown in Figure 2b, PEDF was measured in
supernatant from B16-F10 melanoma cells infected by
Ad-PEDF/Liposome, Ad-PEDF or Ad-null. Obviously,
the expression of PEDF transfected by the Ad-PEDF/
Liposome complexes was much higher than that of Ad-
PEDF and there was noting in Ad-null infected cells.
These results indicated that the Ad-PEDF/Liposome
complexes could increase the expression of PEDF in
B16-F10 melanoma cells.
Then, we used DOTAP and cholesterol liposome-
encapsulated Ad-GFP to infect B16-F10 melanoma cells
with the existence of Ad-neutralizing antibody. The re-
sults showed that the pre-existing neutralizing antibody
failed to block the DOTAP and cholesterol liposome-
encapsulated Ad-GFP infection to B16-F10 melanoma
cells (Figures 2c-e). These findings indicated that the
DOTAP and cholesterol liposome-encapsulated Ad-GFP
can infect CAR-negative cells in a CAR-independent
way.
Enhancement of apoptosis in B16-F10 melanoma cells by
Ad-PEDF/liposome complexes
We determined apoptosis in B16-F10 melanoma cells
infected by Ad-PEDF/Liposome complexes for 72 h
using Flow Cytometry. As shown in Figure 3, there were
almost no apoptotic cells in the control and Ad-Null
group while a low sub-diploid peak can be seen in Ad-
PEDF treated group and the sub-diploid peak became
higher with the ratio of Ad-PEDF/Liposome complexes
treated group at 10 μg: 5 × 107 IFU. These results indi-
cated that Ad-PEDF encapsulated with liposome could
enhance apoptosis, because liposome can improve infec-
tion efficiency of Ad-PEDF in B16-F10 melanoma cells,
with the result of more expression of PEDF to cause
more apoptosis of B16-F10 melanoma cells.
Figure 1 Particle diameter and TEM photo of DOTAP and cholesterol liposome-encapsulated Ad. The complex of Ad and liposome was
visualized by a transmission electron microscope. The naked adenovirus (a) and adenoviral particles encapsulated by DOTAP and cholesterol
liposome (b). Both the Ad/Liposome complex and Ad alone shows average particle diameter of the particles, red line represent for Ad alone;
black line represent for Ad/Liposome complex (c).
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in vivo
We determined the distribution of Ad encapsulated with
liposome by using the luciferase reporting system. As
shown in Figure 4a, we found that the expression of lucif-
erase of the control groups was high in liver and low in
other tissues. However, the luciferase of Ad-luc/Liposome
expressed much higher in lung, and significantly lower
in liver. There was no notable difference in other tis-
sues such as heart, kidney and spleen. This indicated
that Ad encapsulated with liposome could change the
distribution of Ad in vivo, resulting in decreased clear-
ance of Ad by liver and increased gene expression effi-
ciency to lung.Encapsulation with liposome of Ad-PEDF reduces Ad
antibody
For detection of Ad antibody response of Ad-PEDF/
Liposome complexes, we collected the sera from the
treatment groups and controls and measured the Ad
antibody concentration in the sera of each group. As
Figure 4b shown, on day 20 after B16-F10 melanoma
cells injection, at the dilution titer of 1:100, Ad antibody
level of Ad-PEDF/Liposome or Ad-Null/Liposome group
was significantly lower than that of Ad-PEDF group.
This result suggested that the availability of repeated
and systemic administration with Ad-PEDF/Liposome
could effectively reduce the amount of Ad antibody and
inhibit angiogenesis.
Figure 2 The Ad/Liposome complex shows enhanced transfection capacity in B16-F10 cells. B16-F10 cells were transfected at different
liposome and Ad-GFP ratio. After infected for 48 h, the percentage of GFP expression was determined by FACS analysis (a). Three replicates were
performed for each treatment. The data shown are mean ± s.d. (*P < 0.05). Expression of PEDF protein in B16-F10 cells was determined by
western blot (b). Lane1: transfected with Ad-PEDF liposome complex (Ad-PEDF/Liposome) at a ratio of 5 × 107 IFU/10 μg; lane2: transfected with
Ad-PEDF alone (Ad-PEDF); Lane3: untreated. Then, B16-F10 cells were transfected with Ad-GFP (c) and Ad-GFP/Liposome (d) at a ratio of 5 × 107
IFU/10 μg. Besides, neutralizing antibodies of Ad vector pre-incubated B16-F10 cells were also transfected with Ad-GFP/Liposome complex at the
same concentration (d). Ad-GFP/Liposome complex transfection noticeably enhanced the efficacy of Ad than that in Ad-GFP transfected B16-F10
cells. However, neutralizing antibodies against Ad vector only partially downregulated GFP expression (e) and data are expressed as percentages
(f). Bars, SD; columns, mean.
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Ad-PEDF in vivo
After confirmation of the success for Ad encapsulated
with liposome transfer and expression in vitro, as well as
increasing gene expression to lung in vivo, we examined
the antitumor efficacy of Ad-PEDF/Liposome treatment
in a murine pulmonary metastases model. Figure 5a
shows representative images of pulmonary metastases ofB16-F10 melanoma in each treatment group. It was ob-
vious that the mice treated with the Ad-PEDF/Liposome
complexes bore less pulmonary metastatic nodules than
those of mice in other groups. The inhibitory effect on
metastases of Ad-PEDF/Liposome complexes was reflected
in a statistically significant reduction in weight of the
lung compared to other groups. The weight of the lungs
from each group is presented in Figure 5b. The mean
Figure 3 Apoptosis of B16-F10 cells induced by Ad-PEDF/Liposome in vitro. Apoptosis cells were determined by flow cytometry. The
groups are as follow: (a) NS (normal saline), (b) Ad-Null/Liposome, (c) Ad-PEDF, (d) Ad-PEDF/Liposome. Data are expressed as percentages (e). The
Ad-PEDF/Liposome group showed a significant increase in apoptosis compared with other groups (*P < 0.01). Bars, SD; points, mean (n = 3).
Figure 4 Detection of host response followed systemic administration of Ad-luc/Liposome. (a) The expression of luciferase of the control
groups was high in liver and low in other tissues. However, the luciferase of Ad-luc/Liposome expressed much higher in lung, and significantly
lower in liver (*P < 0.01). There was no notable difference in other tissues such as heart, kidney and spleen (P > 0.05). (b) Specific anti-Ad
antibodies in sera. The level of specific anti-Ad immunoglobulins present in the serum of each group was evaluated by ELISA. The values showed
that anti-Ad antibodies in Ad-Null/Liposome and Ad-PEDF/Liposome groups are significantly decreased than Ad-PEDF (*P < 0.01). Bars, SD;
columns, mean (n = 5).
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Figure 5 Anti-cancer effects of Ad-PEDF/Liposome in vivo. (a) Antitumor effects. Tumor-bearing mice were treated with NS, Ad-Null/
Liposome, Ad-PEDF and Ad-PEDF/Liposome. There was a significant difference in lung metastasis between PEDF (Ad-PEDF and Ad-PEDF/
Liposome) treated group and other groups in both number of pulmonary metastatic nodules (b) and lung weight (c) (P < 0.01). There was also a
difference between the Ad-PEDF group and Ad-PEDF/Liposome group (P < 0.05). Bars, SD; points, mean (n = 5). A significant increase in survival
was found in Ad-PEDF/Liposome-treated mice (d) (n = 10, P < 0.05, log-rank test).
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in Ad-PEDF group, 0.98 g in Ad-Null/Liposome group
and 0.82 g in NS group, respectively. Moreover, the
pulmonary metastatic nodules in each mouse were
numbered, and results are presented in Figure 5c. From
day 20 after B16-F10 melanoma cells inoculation, the
number of lung nodules in Ad-PEDF/Liposome treated
mice showed significant differences from those in
controls (p < 0.05). The number of lung nodules in the
Ad-PEDF/Liposome treated group was 5 and the meta-
static tumors above 3 mm occupied 1.3%, in contrast to
44 in Ad-PEDF group, 200 in Ad-Null/Liposome group,
and 200 in normal saline group, in which the metastatic
tumors above 3 mm accounted for 12.17%, 20% and
22%, respectively. These results manifest that Ad-PEDF
encapsulated with liposome can efficiently inhibit the
growth of pulmonary metastases of B16-F10 melanoma
in vivo. Survival time with the complex treatment group
was significantly longer than other groups including the
Ad-PEDF group (Figure 5d).
To further determine the morphologic changes for the
lungs of each treatment group, adjacent sections of lungs
were stained with H&E. As shown in Figure 6a, in nor-
mal saline group, there were a lot of metastatic tumors
with huge volume to oppress the normal tissues of lung
and destroy pulmonary alveoli and terminal bronchioles,
resulting in pneumorrhagia. In Ad-Null/Liposome group,
abundant metastatic nodules occupied normal tissue
of lung to induce lung structure reduction and evendisappearance. Compared with the controls, in the treat-
ment groups including Ad-PEDF and Ad-PEDF/Liposome
complexes, there were sporadic metastatic nodules on the
surface of lung, but they were smaller and fewer with
normal and clear lung structure in Ad-PEDF/Liposome
group. This suggested that encapsulation of liposome
can enhance the therapeutic effectiveness of Ad-encoding
PEDF on pulmonary metastases of B16-F10 melanoma.
To evaluate the result of anti-angiogenesis therapy, frozen
tumor sections were stained with an endothelial-specific
antibody against CD31 as before. The decreased micro-
vessel densities were found in Ad-PEDF/Lipo-treated
tumors. The micro-vessel density was counted in
Figure 6.
To prove whether the anticancer effects of the Ad-
PEDF/Liposome complexes associated with the apoptotic
cells, TUNEL assay was applied. As shown in Figure 7b-c,
there were more green nuclei identified as apoptosis
observed in the Ad-PEDF/Liposome complexes treated
tumor tissue than those in other treated groups (p < 0.05).
This suggests that inhibited pulmonary metastases of B16-
F10 melanoma by the Ad-PEDF/Liposome complexes
may be induced by apoptosis.
Toxicity observation
To evaluate the health status of mice in each group, the
weight of mice was monitored once every 3 days after
mice were treated with Ad-PEDF/Lipo (i.v. administra-
tion of 1 × 108 IFU recombinant adenovirus plus 20 μg
Figure 6 Inhibition of tumor angiogenesis by Ad-PEDF systemic administration. Tumors were harvested from NS (a), Ad-Null/Liposome
(b), Ad-PEDF (c), or Ad-PEDF/Liposome (d) treated mice. Frozen tissue sections were fixed and treated with anti-CD31 antibody. The stained
sections were visualized. Significantly decreased micro-vessels were observed in the Ad-E/Lipo-treated group compared with other groups
(e, *indicates P < 0.05).
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recombinant adenovirus), Ad-null/Lipo (i.v. administration
of 1 × 108 IFU plus 20 μg liposome) and normal saline. No
significant differences in weights were found among all
the groups (Figure 8a). Furthermore, we determined
whether encapsulation of liposome had the toxic and side
effect on other normal tissues of Ad-PEDF/Liposome
complexes with H&E staining. The organs including heart,
liver, spleen and kidney kept primitively normal without
inflammatory cells infiltration and necrosis (Figure 8b).
This result indicated that Ad encapsulated with liposome
appeared no obvious toxic reaction to normal tissues.
Discussion
Melanoma which derived from neuroectoderm has a
high malignancy with poor prognosis, due to the vascular
and lymphatic metastasis during the late stage [6]. It still
remains a major clinical challenge in treating melanoma,and the existing therapeutic protocols are limited. Thus,
the development of novel treatment approaches is
required [3]. Angiogenesis has been shown to play a key
role in tumor growth and metastasis. PEDF plays an
important role in the process of angiogenesis of melan-
oma, which could inhibit endothelial cell proliferation
and migration toward many angiogenic inducer [17],
and then prevents melanoma growth via angiogenesis
inhibition [2,18]. PEDF displays broad anti-tumor activ-
ity not only based on targeting of the tumor microenvir-
onment (anti-angiogenic action) but also the tumor
cells (direct anti-tumor action) [33]. Loss of PEDF
enables migration, invasion and metastatic spread of
melanoma [33], and constitutive over expression of
PEDF could inhibit melanoma growth and metastasis
[34]. So PEDF is an ideal target for treatment of melanoma,
and it does have good efficacy on inhibition metastatic
spread of melanoma in our study.
Figure 7 Histological analysis of tumors. (a) The Hematoxylin and eosin (H&E) staining of lung tissues. After mice were sacrificed histological
sections were taken from lungs of mice, and analyzed at × 100 magnification. The mice treated with Ad-PEDF/Liposome showed a significant
inhibition of the size of to the metastasis of B16-F10. (b) Detection of apoptotic cancer cells in B16-F10 metastasis in C57 BL/6 mice using TUNEL
analysis. The percentage of apoptosis was determined by counting the number of apoptotic cells and dividing by the total number of cancer
cells in the field (five high power fields/slide). (c) Percent apoptosis in each group. The group treated with Ad-PEDF/Liposome resulted in
significantly increased apoptosis compared to that of other groups (*P < 0.01). Bars, SD; columns, mean.
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proliferating endothelial cells and cancer cells, however,
intravenous and prolonged administration is required
for better benefits in clinically administration. In this
study, we utilized adenovirus to encode PEDF to inhibit
angiogenesis of B16-F10 melanoma, due to its high gene
transfection efficiency [35,36]. However the coxsackievirus-
adenovirus receptor (CAR) levels are often low in tumor
cells and could not be detected in the endothelial cells
[37,38]. Therefore, we performed a systemic and repeated
administration with cationic liposome-encapsulated adeno-
virus to explore target and the antitumor effects in
pulmonary metastases of B16-F10 melanoma model.
Cationic liposome can not only protect negative macro-
molecular drugs, but also deliver them to target cells[39-41]. Generally, the binding between adenovirus and
targeting cells was dependent on the adenoviral fiber knob
with CAR of the cell surface [31]. Cationic liposome can
mask adenovirus and increase the efficiency of gene
transfer in vitro and broaden vector tropism to various
cells and tissues, as well as reduce immunogenicity
in vivo [42-44], and thus provides a feasible way to
improve the ability of adenovirus to infect the special
tissue and cancer cells. Previous investigations have
shown that complexation of Ad vectors with cationic
lipids can improve infection of cultured cells [45-47].
Moreover, cationic liposome enhanced infection of Ad
vectors mainly by improving the cellular uptake, altered
bio-distribution and reduced immunogenicity of adeno-
virus [28,48,49]. In this study, the liposome was composed
Figure 8 Toxicity observation. (a) Body weights of mice were plotted and the curve of the Ad-PEDF/Lipo-treated and Ad-null/Lipo-treated
group paralleled very closely to that of the Ad-PEDF group and ns group with no significant differences among them (P > 0.05). (b) The
Hematoxylin and eosin (H&E) staining of heart, liver, spleen and kidney. After mice were sacrificed histological sections were taken from lungs of
mice, and analyzed at × 200 magnification. The organs kept primitively normal without inflammatory cells infiltration and necrosis in each group.
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performance and its stabilization separately. Cholesterol
incorporation into DOTAP liposome enhanced stability
and uptake of the complexes of Ad vector with liposome
and further improved the infection efficiency of CAR-
deficient tumor cells [32]. Besides, we prepared the
cationic liposome to encapsulate Ad vector and applied
to detect bio-distribution of the complexes in vivo.
Then we found that significantly more expression in
lung and less expression in liver than Ad used alone.
This suggested that the cationic liposome could alter
the bio-distribution of Ad vector, which was in accord
with the previous studies [49-51].
Furthermore, we investigated the anti-cancer effect by
gene therapy mediated by the Ad-PEDF/Liposome com-
plexes to pulmonary metastases of B16-F10 melanoma,
on the basis of Ad vector encapsulated with cationic
liposome increasing gene expression to lung. In vivo,
Ad-PEDF/Liposome showed stronger inhibited angio-
genesis, metastases of B16-F10 melanoma and increased
apoptosis, as well as the growth of metastatic tumors
than Ad-PEDF used alone. This result indicated that
liposome-encapsulated Ad could prolong the expression
of PEDF and there is more secreted transduction and
PEDF secretion or because PEDF secretion is localized
to the lung/tumor, these are need to be confirmed in
future experiments. These findings support that thegene therapy strategy of anti-angiogenesis based on the
cationic liposome is feasible for pulmonary metastases
of B16-F10 melanoma therapy.
However, there is another problem that adenoviral
clearance due to vector immunogenicity in vivo induces
the failure of repeated administration of recombinant
adenovirus [52]. In our research, Ad antibody levels
from complex-injected mice were significantly lower
than those from Ad-PEDF injected alone. The cationic
liposome has advantage as a physical barrier to Ad vec-
tor and protects Ad-PEDF to escape from host immune
clearance and extends blood circulation time. Therefore,
Ad-PEDF/Liposome complexes can possibly be repeatedly
applied via intravenous administration. These results indi-
cated that anti-angiogenesis therapy medicated by Ad-
encoding PEDF encapsulated with the cationic liposome
profited to reduce tumor angiogenesis and metastases of
B16-F10 melanoma. However, the complexes were unable
to inhibit tumor growth completely. It is necessary to
optimize liposomal formations and therapeutic scheme to
gain better therapeutic efficacy.
Conclusion
In summary, we found advantages in the application of
the cationic liposome-encapsulated Ad vectors to gene
therapy. Anti-angiogenesis gene therapy mediated by
adenovirus with the cationic liposome can be used to
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http://www.translational-medicine.com/content/11/1/86synergize with PEDF and further inhibit the growth of
B16-F10 melanoma. In the future, further improvements
in formation method of the cationic liposome, as well as
advancement of Ad vectors will take out to inhibit
tumor growth fully and apply to other antitumor
models, through optimizing the encapsulation of the
cationic liposome with Ad.
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